A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton’s Tyrosine kinase inhibitor ibrutinib in combination with nab-praclitaxel and gemcitabine versus placebo in combination with nab-praclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic Adenocarcinoma - Regional Cancer Care Associates LLC

Clinical Trials

A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton’s Tyrosine kinase inhibitor ibrutinib in combination with nab-praclitaxel and gemcitabine versus placebo in combination with nab-praclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic Adenocarcinoma

Type of Cancer
Pancreatic
Locations
Bethesda
Sponsor
Pharmacyclics LLC
Protocol Number
PCYC-1137-CA
Cancer Diagnosis
To Learn More Call
201-510-0910